- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models - ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer be controlled with hormone therapy. Even in such situations, effective ...

- ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting - Actinium is ...

- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology withcontinued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy, enabling ...

- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi ® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination - ...

The University College London (UCL) sponsored study evaluates safety, tolerability and radiation dosimetry of an investigational alpha‑emitting PSMA‑targeted radiopharmaceutical therapy, building on ...

DUBLIN, Ohio, April 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for ...

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced compelling ...

- ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression ...

NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of differentiated targeted radiotherapies, today ...